Index of drugs

Adults: treatment of cortical myoclonus, treatment of central and peripheral vertigo. Children: treatment of dyslexic disorders simultaneously with speech therapy.

1 tabl powl. contains 800 mg or 1200 mg of piracetam; drug contains lactose.

Nootropic medicine - ring derivative of gamma-aminobutyric acid (GABA). The basic mechanism of action of Piracetam is not specific for a particular type of cell or for a specific organ. In phospholipid membrane models, piracetam binds physically, proportional to the dose size, to the polar group, initiating the process of reconstructing the membrane structure by forming mobile complexes of drug molecules and phospholipids. This probably improves the stability of the membrane, thanks to which membrane or transmembrane proteins maintain or regain the appropriate three-dimensional structure allowing them to fulfill their correct function. Piracetam acts on nerve cells and the vascular system. It enhances different processes of neuron signaling, primarily through the modulation of density and activity of postsynaptic receptors. It modifies the rheological properties of blood, affecting platelets, red blood cells and the walls of blood vessels. It increases the flexibility of erythrocytes and reduces platelet aggregation, reduces the adherence of erythrocytes to the walls of blood vessels and capillary contraction. After oral administration, piracetam is absorbed quickly and to a large extent. Accepted on an empty stomach, it reaches C_max after 1 hour from serving. The absolute bioavailability is close to 100%. Piracetam does not bind to plasma proteins. It penetrates the blood-brain barrier; T indicator_max for cerebrospinal fluid is about 5 hours, and T_0,5 about 7.7 h. It penetrates all tissues except adipose tissue, penetrates the placental barrier and through the cell membranes of isolated erythrocytes. It is not metabolized. It is excreted mainly in the urine (80-100% of the dose). T_0,5 in the blood is 5 hours.

Hypersensitivity to Piracetam, other pyrrolidone derivatives or to any of the excipients. Brain hemorrhage. End-stage renal failure. Huntington's chorea.

Due to the effect of piracetam on platelet aggregation, caution should be exercised when administering to patients with severe hemorrhage, with the risk of bleeding eg in peptic ulcer of the stomach and intestines, with haemostatic disorders, with a history of haemorrhagic stroke, undergoing major surgery, including procedures dental surgery. Use with caution in patients with impaired renal function. Elderly patients treated for longer periods of time need regular creatinine clearance and possible dose modification. Do not suddenly discontinue treatment in patients treated for myoclonus to prevent sudden return of myoclonus or generalized seizures associated with sudden discontinuation of piracetam. The medicine contains approximately 1.5-3 mmol (35-70 mg) of sodium at a dose of 24 g piracetam - this should be taken into account in patients on a controlled diet or with reduced renal function. Due to the lactose content, the drug should not be used in patients with rare hereditary galactose intolerance, lactase deficiency (Lapp type) or malabsorption of glucose-galactose.

Piracetam penetrates through the placental barrier. The concentration of the drug in the blood of newborns is equal to approximately 70-90% of the concentration in the mother's blood. Piracetam should not be administered to pregnant women unless there are clear indications and when the benefits of taking the drug outweigh the risks and the clinical condition of the pregnant woman requires treatment with piracetam. Piracetam passes into human milk - avoid using it during breastfeeding or stop breastfeeding during treatment.

Common: nervousness, hyperkinesia, weight gain. Uncommon: depression, drowsiness, asthenia.Not known: haemorrhagic disorders, anaphylactoid reactions, hypersensitivity, agitation, anxiety, confusion, hallucinations, ataxia, balance disorders, epilepsy severity, headache, insomnia, dizziness, abdominal pain, epigastric pain, diarrhea, nausea, vomiting , angioneurotic edema, dermatitis, pruritus, urticaria.

Orally.Treatment of cortical myoclonus. Adults: Initially 7.2 g / day, increasing every 3 or 4 days by 4.8 g / day, up to a maximum dose of 24 g / day. The daily dose is given in 2-3 divided doses. In combination with other antimusconics, doses of other medicines should be maintained at the recommended therapeutic doses; if a clinical improvement is achieved and it is possible - doses of other drugs should be reduced. In patients with myoclonus, the symptoms may evolve over time, so every 6 months an attempt to reduce the dose or discontinue the drug should be made. For this purpose, the piracetam dose should be reduced by 1.2 g every two days to prevent sudden relapse.Treatment of central and peripheral vertigo. Adults: 2.4 g / day in 3 divided doses of 800 mg for 8 weeks.Treatment of dyslexic disorders. Children 8-13 years: 3.2 g / day in 2 divided doses, simultaneously with speech therapy.Special groups of patients. In patients with renal insufficiency, the daily dose should be determined individually depending on the creatinine clearance (CCr) - CCr> 80 ml / min: usually the recommended dose, divided into 2 to 4 doses per day; CCr 50-79 ml / min: 2/3 of the usual recommended dose, divided into 2 to 3 doses per day; CCr 30-49 ml / min: 1/3 of the usual recommended dose, divided into 2 doses per day; CCr <30 ml / min: 1/6 of the usual recommended dose, administered once daily; end-stage renal failure - contraindicated. In patients with liver failure, no dose adjustment is required.Way of giving. The medicine can be taken during a meal or during a break between meals; drink with a small amount of water; do not chew. Always take at the same time.